Founded in November, 1999, Zhejiang Kangrun Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Hangzhou Huadong Medicine Group, with a registered capital of CNY 13.5762 million, 36,000m2 of lands and over 10,000m2 of buildings. We were founded as State-run Anji Pharmaceutical Factory in 1971, thus we have a manufacturing history of 40 years. As a key hi-tech enterprise supported by Chinese government, Zhejiang Kangrun Pharmaceutical Co., Ltd. is mainly engaged in the production, research, development and trade of proprietary Chinese medicines, natural products and chemical synthetic drugs, etc.

At present, we own more than 30 License numbers of proprietary Chinese medicines, which are divided into 7 preparations such as tablets, capsules, granules and oral liquid preparation, etc; all of them got the certificates of Chinese GMP. Especially, our Jinxuan Liyan capsules and Pingchuan Yiqi capsules (new traditional Chinese medicine, invention patented product) are national exclusive products of China. The main patented products of our company include Jinguoyin, Yangxue Anshen Syrup, Shujin Huoxue Capsules, Gentamicin Procaine Vitamin B12 Capsules and so on. We have successfully established a nation-wide product network by now.

Our natural products include coenzyme Q10 (product of national torch plan), liquorice antibacterial extract (products of small and medium-sized enterprise innovation fund of Ministry of science and technology), huperzine A (key project of innovation fund of Ministry of science and technology), Resveratrol (provincial innovation fund product), paclitaxel, oridonin, indirubin, sirolimus and other dozens kinds of natural extract monomers. Moreover, , we also produce more than ten kinds of natural drug extracts like apocynum venetum extract and astragalus extract, which are well sold in more than 10 countries in the world.

The main Chemical synthetic products of our company include pramipexole dihydrochloride, rivaroxaban, everolimus, temsirolimus, pimecrolimus and other chemical synthetic APIs; furthermore, we have applied for the New Drug Applications of pramipexole, rivaroxaban and everolimus in China, and we have handed the DMF files of everolimus and temsirolimus to FDA. According to our estimation, some of the production lines of our products will be approved by FDA in next 2-3 years.

Since our foundation, we have been taking "first or unique" as management policy, and “total quality management as criterion, technology as guidance and excellent service as tenet, strive to produce quality and customer-satisfied products with reasonable costs” as the philosophy of enterprise. We are working hard to make Zhejiang Kangrun Pharmaceutical Co., Ltd. a modern and international hi-tech pharmaceutical enterprise!